PUBLISHER: DelveInsight | PRODUCT CODE: 1128296
PUBLISHER: DelveInsight | PRODUCT CODE: 1128296
"Benralizumab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about benralizumab for Chronic Spontaneous Urticaria in seven major markets. A detailed picture of the benralizumab for Chronic Spontaneous Urticaria in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the benralizumab for Chronic Spontaneous Urticaria. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the benralizumab market forecast analysis for Chronic Spontaneous Urticaria in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Chronic Spontaneous Urticaria.
Fasenra (benralizumab) is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death).
Fasenra is AstraZeneca's first respiratory biologic, now approved as an add-on maintenance treatment for severe eosinophilic asthma in the US, EU, Japan, and other countries, with further regulatory reviews ongoing. In the US, Fasenra is approved for self-administration using the Fasenra Pen. In the EU, Fasenra is approved for self-administration in either the single-use, prefilled syringe, or the Fasenra Pen. Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Kirin Co., Ltd., Japan. MedImmune is the worldwide biologics research and development arm of AstraZeneca, and thus, both AstraZeneca and MedImmune are working together for the development of benralizumab.
The three new trials for Fasenra in skin diseases include two 'phase II trials' to assess the potential of the medicine in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU); and a phase III trial in bullous pemphigoid (BP).
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Benralizumab Analytical Perspective by DelveInsight
This report provides a detailed market assessment of benralizumab for Chronic Spontaneous Urticaria in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of benralizumab for Chronic Spontaneous Urticaria covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions